



THE WHITE HOUSE  
WASHINGTON

# COVID-19 Press Briefing


April 2, 2021



# The Vaccination Progress Report

7-day average daily doses administered by week as of 4/1/2021\*

Doses per day



\*7-day average from March 3 – March 9 was 2.2M



# Daily Change in COVID-19 Cases, US

January 22, 2020 – March 31, 2021

TOTAL Cases Reported Since 1/22/20

30,277,908

NEW Cases Reported to CDC on 3/31/21

64,149

Change in 7-Day Case Average

+8.4%


Current 7-Day Case Average (3/25/21 - 3/31/21)

62,167

Prior 7-Day Case Average (3/18/21 - 3/24/21)

57,343

Peaks in New Cases and Highest 7-Day Moving Average		
	Highest Daily Number of New Cases	Highest 7-Day Moving Average
<b>Current</b>	315,163 (1/8/21)	250,446 (1/11/21)
<b>2<sup>nd</sup> Peak</b>	75,319 (7/17/20)	67,337 (7/23/20)
<b>1<sup>st</sup> Peak</b>	42,568 (4/6/20)	31,915 (4/12/20)



# New Admissions of Patients with Confirmed COVID-19

August 1, 2020 – March 30, 2021

Patients Currently Hospitalized with COVID on 3/30/21

33,748

New Admissions on 3/30/21

5,261

Peak in New Admissions (1/5/21)

17,993

Change in 7-Day Average of New Admissions


+4.8%

Current 7-Day Average of New Admissions (3/24/21 - 3/30/21)

4,948

Prior 7-Day Average of New Admissions (3/17/21 - 3/23/21)

4,722



# Daily Change in COVID-19 Deaths, United States

January 22, 2020 – March 31, 2021

TOTAL Deaths Reported Since 1/22/2020

549,098

NEW Deaths Reported to CDC on 3/31/21

917

Change in 7-Day Death Average

-7.7%

Current 7-Day Death Average (3/25/21 - 3/31/21)


880

Prior 7-Day Death Average (3/18/21 - 3/24/21)

953


Forecasted Total Deaths by 4/24/21

565,000 to 585,000





**WEAR A MASK**



**STAY 6 FEET APART**



**AVOID CROWDS**



**AVOID TRAVEL**

# **COVID-19 Vaccine Update: More Positive News from “Real World” Studies and Clinical Trials**

---

- **MMWR: Messenger RNA (mRNA) COVID-19 vaccines 90% effective in real world conditions**
- **Pfizer reports vaccine 100% protective in adolescents**
- **Pfizer reports vaccine protection in adults up to 6 months**





## **Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021**

- Prospective study; n=3,950
- Participants self-collected nasal swabs each week for RT-PCR laboratory testing
- mRNA vaccine effectiveness of full immunization ( $\geq 14$  days after second dose) was 90% against SARS-CoV-2 infections regardless of symptom status; 80% after one dose
- 3 PCR-confirmed infections occurred during 78,902 person-days with full immunization (0.04/1,000 person-days)





## News Release

April 1, 2021

# **Pfizer and Biontech Confirm High Efficacy and No Serious Safety Concerns Through up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study**

- **91.3% efficacy against COVID-19, measured seven days through up to six months after the second dose**
- **~95-100% efficacy against severe disease**
- **No safety concerns to date**
- **In South Africa (N=800), 6 cases of B.1.351 variant in placebo group and 0 in vaccinated group**



# **Rationale for SARS-CoV-2 Trials in Pediatric and Adolescent Populations**

---

- **Goal: SARS-CoV-2 vaccine for entire U.S. population**
- **Children and adolescents make up 22% of the U.S. population\***
- **Emerging data suggests that vaccination prevents asymptomatic carriage, thus reversing pandemic more rapidly**

\*census.gov





March 31, 2021

News Release

# **Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents**

- In participants aged 12-15 years, BNT162b2 was well-tolerated and **demonstrated 100% efficacy (18 cases of COVID-19 in placebo group and 0 cases in vaccine group)** and robust antibody responses; n=2,260
- Companies plan to submit data to FDA as soon as possible to request expansion of the Emergency Use Authorization (EUA) for the vaccine
- Study underway in children aged 6 months to 11 years
  - 5-to-11 year old cohort started dosing last week; 2-to-5 year old cohort to begin next week



# COVID-19 Public Education Campaign



Brought to you by the U.S. Department of Health and Human Services





# Goals

1. **Educate** on how to protect yourself & slow the spread of COVID-19

2. **Build trust** in vaccines with accurate information from trusted sources

3. **Increase awareness** about how to get vaccinated when ready



## ■ Role of trusted messengers

Trusted community members: essential for **health education & empowerment**

- Effectively deliver messages and strategies
- Validate the credibility of information
- Address mis- and disinformation
- Create a feedback loop for addressing questions and concerns
- Bridge the gap between healthcare providers and patients



Friends



Pharmacists



Nurses



Faith Community



# COVID-19 Community Corps



- Galvanize trusted voices in communities
- Provide toolkits & resources to organize & educate
- Receive scientific updates, infographics, factsheets, & tools on ways to help people get registered and vaccinated



Join us online at  
**WeCanDoThis.hhs.gov**



5







THE WHITE HOUSE  
WASHINGTON

WH.GOV